Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proscavax in Localized Prostate Cancer
NCT03579654Phase 2Unknown
- Sponsor
- OncBioMune Pharmaceuticals, Inc.
- Start
- Feb 2019
- Primary completion
- Feb 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of prostate-specific antigen + interleukin-2 + granulocyte-macrophage colony-stimulating factor in prostate cancer (PCa), sponsored by OncBioMune Pharmaceuticals, Inc.. Status: unknown.
02
Drugs
prostate-specific antigen + interleukin-2 + granulocyte-macrophage colony-stimulating factor
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03579654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03579654.